ArticleJournal of thoracic disease2025
Bibliometric examination of neoadjuvant immunotherapy in esophageal cancer: insights, trends, collaborative networks, and prospective directions.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal malignant tumors are highly aggressive gastrointestinal tumors dominated by epidermal squamous cell carcinoma and adenocarcinoma, which are characterized by insidious early symptoms, easy recurrence and metastasis, and poor prognosis. Conventional therapies do not respond well, and neoadjuvant immunotherapy offers a new treatment modality. This study uses bibliometrics to help clinicians grasp the current status, recent progress, and emerging trends in the field, serving as a reference for future research. Methods: A total of 562 articles included in the Web of Science Core Collection (WOSCC) database were searched to systematically review the global research trends of neoadjuvant immunotherapy for esophageal cancer (EC) from January 2008 to December 2024. Bibliometric analysis was carried out by "R Studio", "CiteSpace 5.8 R5", "VOSviewer 1.6.19", and other software, and multi-dimensional analysis of researchers, institutions, countries, and published literature was performed. Results: The investigation of neoadjuvant immunotherapy for EC has become a central focus within the field, experiencing significant advancements in recent years. China and the United States have played a leading role in research in this area, while the contributions of the United Kingdom, Germany, and Japan have steadily increased. Immunotherapy mode, efficacy evaluation, and biomarker exploration are current research hotspots. Conclusions: In the future, we should continue to strengthen global cooperation in this field and further promote the development of large-scale phase III multicenter clinical trials. We need to establish standardized efficacy evaluation criteria and explore more clinically significant biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.